Janux Therapeutics Inc（JANX）股票分析JANXJanux Therapeutics Inc

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Janux Therapeutics Inc (JANX) is currently a hold. The stock is priced at $16.66, significantly below the average analyst price target of $35 to $55, suggesting potential upside. However, the RSI is at 39.016, indicating the stock is nearing oversold territory, which could lead to a rebound. The main risk is the company's negative earnings trend, with a reported EPS of -0.35 in the last quarter, missing expectations by $0.09, which raises concerns about profitability and future growth.